This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through June 1, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical-devices: Archive
ESTA Shares Dip Despite FDA Filing for Motiva Breast Reconstruction
by Zacks Equity Research
Establishment Labs files Motiva breast implants with the FDA for reconstruction, targeting expansion beyond elective augmentation into a clinically necessary market.
medical medical-devices
HIMS Scales AI-Enabled Care as Platform Depth and Engagement Expand
by Debanjana Dey
Hims & Hers accelerates AI-powered care with new tools, deeper data use and platform expansions into diagnostics and specialties.
medical medical-devices
RBOT Enters Strategic Software Partnership to Streamline Development
by Zacks Equity Research
Vicarious Surgical inks a software execution partnership to streamline development, cut costs and improve predictability.
medical medical-devices
Tilly's (TLYS)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Are Options Traders Betting on a Big Move in UFP Technologies Stock?
by Zacks Equity Research
Investors need to pay close attention to UFP Technologies stock based on the movements in the options market lately.
medical medical-devices
BSX vs. RMD: Which Medical Device Stock Is the Stronger Play Now?
by Moumi Mondal
Boston Scientific edges out Resmed as WATCHMAN momentum, EP gains and acquisitions fuel stronger recent price performance in a growing medical device market.
medical medical-devices
Should Myriad Genetics Stock Stay in Your Portfolio Right Now?
by Zacks Equity Research
MYGN shows growth potential from new genetic test launches and a refreshed CCC strategy, but revenue pressure from GeneSight coverage loss remains a drag.
medical medical-devices
Reasons to Add Cooper Companies Stock to Your Portfolio Now
by Zacks Equity Research
COO's revenues are showing strong growth as MyDay and MiSight drive momentum, while restructuring savings and buybacks bolster long-term upside despite near-term risks.
medical medical-devices
3 Stocks Likely to Gain From Rising HSA Contribution & Medicare Premium
by Indrajit Bandyopadhyay
Rising HSA limits and higher Medicare premiums in 2026 could lift demand for chronic care devices from DexCom, ResMed and Masimo.
medical medical-devices
Reasons to Hold Veeva Systems Stock in Your Portfolio for Now
by Zacks Equity Research
VEEV's strong Q3, expanding AI strategy and major life sciences partnerships fuel growth despite rising costs.
medical medical-devices